ASX - By Stock
|
PAR |
Re:
Ampio -v- Zilosul
|
|
Zenox
|
39 |
15K |
5 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
39
|
15K
|
5
|
|
ASX - By Stock
|
MSB |
Re:
Ann: Quarterly Activities/Appendix 4C Cash Flow Report
|
|
Zenox
|
190 |
62K |
10 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
190
|
62K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Quarterly Update and Appendix 4C - quarterly
|
|
Zenox
|
36 |
13K |
12 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
36
|
13K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Ampio -v- Zilosul
|
|
Zenox
|
39 |
15K |
14 |
02/05/22 |
02/05/22 |
ASX - By Stock
|
39
|
15K
|
14
|
|
ASX - By Stock
|
PAR |
Re:
Something afoot at PAR?
|
|
Zenox
|
54 |
25K |
1 |
22/04/22 |
22/04/22 |
ASX - By Stock
|
54
|
25K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Something afoot at PAR?
|
|
Zenox
|
54 |
25K |
7 |
22/04/22 |
22/04/22 |
ASX - By Stock
|
54
|
25K
|
7
|
|
ASX - By Stock
|
PAR |
Re:
Something afoot at PAR?
|
|
Zenox
|
54 |
25K |
20 |
20/04/22 |
20/04/22 |
ASX - By Stock
|
54
|
25K
|
20
|
|
ASX - By Stock
|
PAR |
Re:
Fast Track
|
|
Zenox
|
17 |
8.4K |
18 |
13/04/22 |
13/04/22 |
ASX - By Stock
|
17
|
8.4K
|
18
|
|
ASX - By Stock
|
PAR |
Re:
Fast Track
|
|
Zenox
|
17 |
8.4K |
14 |
12/04/22 |
12/04/22 |
ASX - By Stock
|
17
|
8.4K
|
14
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
15 |
05/04/22 |
05/04/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
15
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
1 |
04/04/22 |
04/04/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
1
|
|
ASX - By Stock
|
TLX |
Re:
Shorters discover Telix
|
|
Zenox
|
234 |
85K |
3 |
30/03/22 |
30/03/22 |
ASX - By Stock
|
234
|
85K
|
3
|
|
ASX - By Stock
|
TLX |
Re:
How low will it go?
|
|
Zenox
|
132 |
59K |
0 |
28/03/22 |
28/03/22 |
ASX - By Stock
|
132
|
59K
|
0
|
|
ASX - By Stock
|
TLX |
Re:
How low will it go?
|
|
Zenox
|
132 |
59K |
1 |
27/03/22 |
27/03/22 |
ASX - By Stock
|
132
|
59K
|
1
|
|
ASX - By Stock
|
TLX |
Re:
How low will it go?
|
|
Zenox
|
132 |
59K |
0 |
26/03/22 |
26/03/22 |
ASX - By Stock
|
132
|
59K
|
0
|
|
ASX - By Stock
|
PAR |
Re:
Ann: UK ethics and regulatory approval for Phase 3 study
|
|
Zenox
|
5 |
3.4K |
10 |
17/03/22 |
17/03/22 |
ASX - By Stock
|
5
|
3.4K
|
10
|
|
ASX - By Stock
|
PAR |
Re:
Ann: UK ethics and regulatory approval for Phase 3 study
|
|
Zenox
|
5 |
3.4K |
6 |
17/03/22 |
17/03/22 |
ASX - By Stock
|
5
|
3.4K
|
6
|
|
ASX - By Stock
|
PAR |
Re:
What do they want?
|
|
Zenox
|
32 |
14K |
12 |
14/03/22 |
14/03/22 |
ASX - By Stock
|
32
|
14K
|
12
|
|
ASX - By Stock
|
TLX |
Re:
ASX 200 and Fund Managers
|
|
Zenox
|
9 |
4.8K |
9 |
10/03/22 |
10/03/22 |
ASX - By Stock
|
9
|
4.8K
|
9
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Clarification of recent analyst report on Patent Protection
|
|
Zenox
|
59 |
26K |
12 |
10/03/22 |
10/03/22 |
ASX - By Stock
|
59
|
26K
|
12
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Clarification of recent analyst report on Patent Protection
|
|
Zenox
|
59 |
26K |
16 |
09/03/22 |
09/03/22 |
ASX - By Stock
|
59
|
26K
|
16
|
|
ASX - By Stock
|
TLX |
Re:
Looking to buy TLX
|
|
Zenox
|
12 |
4.5K |
1 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
12
|
4.5K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Paradigm patent rejection
|
|
Zenox
|
87 |
29K |
13 |
07/03/22 |
07/03/22 |
ASX - By Stock
|
87
|
29K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: S&P DJI Announces March 2022 Quarterly Rebalance
|
|
Zenox
|
26 |
8.4K |
5 |
04/03/22 |
04/03/22 |
ASX - By Stock
|
26
|
8.4K
|
5
|
|
ASX - By Stock
|
PAR |
Re:
Why are people selling?
|
|
Zenox
|
41 |
15K |
1 |
04/03/22 |
04/03/22 |
ASX - By Stock
|
41
|
15K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Why are people selling?
|
|
Zenox
|
41 |
15K |
2 |
04/03/22 |
04/03/22 |
ASX - By Stock
|
41
|
15K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Why are people selling?
|
|
Zenox
|
41 |
15K |
17 |
03/03/22 |
03/03/22 |
ASX - By Stock
|
41
|
15K
|
17
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
10 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
10
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
9 |
01/03/22 |
01/03/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
9
|
|
ASX - By Stock
|
APX |
Re:
Ann: Investor Presentation
|
|
Zenox
|
247 |
113K |
15 |
24/02/22 |
24/02/22 |
ASX - By Stock
|
247
|
113K
|
15
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
5 |
17/02/22 |
17/02/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
5
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
3 |
16/02/22 |
16/02/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
3
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
0 |
16/02/22 |
16/02/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
0
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
10 |
16/02/22 |
16/02/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
10
|
|
ASX - By Stock
|
PAR |
Re:
research reports and media
|
|
Zenox
|
4.1K |
1.9M |
6 |
16/02/22 |
16/02/22 |
ASX - By Stock
|
4.1K
|
1.9M
|
6
|
|
ASX - By Stock
|
PAR |
Re:
PAR General discussion
|
|
Zenox
|
339 |
138K |
13 |
04/02/22 |
04/02/22 |
ASX - By Stock
|
339
|
138K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: Paradigm AGM Presentation
|
|
Zenox
|
31 |
13K |
1 |
25/01/22 |
25/01/22 |
ASX - By Stock
|
31
|
13K
|
1
|
|
ASX - By Stock
|
PAR |
Re:
Should PAR revive the inhaled PPS formulation?
|
|
Zenox
|
4 |
1.7K |
3 |
20/01/22 |
20/01/22 |
ASX - By Stock
|
4
|
1.7K
|
3
|
|
ASX - By Stock
|
PAR |
Should PAR revive the inhaled PPS formulation?
|
|
Zenox
|
4 |
1.7K |
2 |
20/01/22 |
20/01/22 |
ASX - By Stock
|
4
|
1.7K
|
2
|
|
ASX - By Stock
|
PAR |
Re:
Big pharma deal incoming.
|
|
Zenox
|
39 |
16K |
6 |
19/01/22 |
19/01/22 |
ASX - By Stock
|
39
|
16K
|
6
|
|
ASX - By Stock
|
MSB |
Re:
Silviu Itescu The Legend
|
|
Zenox
|
880 |
214K |
11 |
09/01/22 |
09/01/22 |
ASX - By Stock
|
880
|
214K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Silviu Itescu The Legend
|
|
Zenox
|
880 |
214K |
11 |
09/01/22 |
09/01/22 |
ASX - By Stock
|
880
|
214K
|
11
|
|
ASX - By Stock
|
MSB |
Re:
Silviu Itescu The Legend
|
|
Zenox
|
880 |
214K |
27 |
09/01/22 |
09/01/22 |
ASX - By Stock
|
880
|
214K
|
27
|
|
ASX - By Stock
|
MSB |
Re:
Cell Therapy News/Articles
|
|
Zenox
|
17K |
6.7M |
27 |
23/12/21 |
23/12/21 |
ASX - By Stock
|
17K
|
6.7M
|
27
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL
|
|
Zenox
|
45 |
16K |
21 |
20/12/21 |
20/12/21 |
ASX - By Stock
|
45
|
16K
|
21
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL
|
|
Zenox
|
45 |
16K |
13 |
18/12/21 |
18/12/21 |
ASX - By Stock
|
45
|
16K
|
13
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL
|
|
Zenox
|
45 |
16K |
19 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
45
|
16K
|
19
|
|
ASX - By Stock
|
PAR |
Re:
Ann: PAR REPORTS POSTIVE TOPLINE RESULTS IN HEART FAILURE MODEL
|
|
Zenox
|
45 |
16K |
14 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
45
|
16K
|
14
|
|
ASX - By Stock
|
MSB |
Re:
Ann: FDAs OTAT Agrees to Primary Endpoint for Back Pain
|
|
Zenox
|
408 |
124K |
25 |
16/12/21 |
16/12/21 |
ASX - By Stock
|
408
|
124K
|
25
|
|
ASX - By Stock
|
APX |
Re:
MACQUARIE downgrades APX to Underperform from Neutral
|
|
Zenox
|
174 |
101K |
7 |
15/12/21 |
15/12/21 |
ASX - By Stock
|
174
|
101K
|
7
|
|